Multimodal therapy for complete regression of malignant melanoma using constrained nonlinear optimal dynamic inversion

Using a realistic nonlinear mathematical model for melanoma dynamics and the technique of optimal dynamic inversion (exact feedback linearization with static optimization), a multimodal automatic drug dosage strategy is proposed in this paper for complete regression of melanoma cancer in humans. The proposed strategy computes different drug dosages and gives a nonlinear state feedback solution for driving the number of cancer cells to zero. However, it is observed that when tumor is regressed to certain value, then there is no need of external drug dosages as immune system and other therapeutic states are able to regress tumor at a sufficiently fast rate which is more than exponential rate. As model has three different drug dosages, after applying dynamic inversion philosophy, drug dosages can be selected in optimized manner without crossing their toxicity limits. The combination of drug dosages is decided by appropriately selecting the control design parameter values based on physical constraints. The process is automated for all possible combinations of the chemotherapy and immunotherapy drug dosages with preferential emphasis of having maximum possible variety of drug inputs at any given point of time. Simulation study with a standard patient model shows that tumor cells are regressed from 2 x 107 to order of 105 cells because of external drug dosages in 36.93 days. After this no external drug dosages are required as immune system and other therapeutic states are able to regress tumor at greater than exponential rate and hence, tumor goes to zero (less than 0.01) in 48.77 days and healthy immune system of the patient is restored. Study with different chemotherapy drug resistance value is also carried out. (C) 2014 Elsevier Ltd. All rights reserved.

A new microscopic insight into membrane penetration and reorganization by PETIM dendrimers

Dendrimers are highly branched polymeric nanoparticles whose structure and topology, largely, have determined their efficacy in a wide range of studies performed so far. An area of immense interest is their potential as drug and gene delivery vectors. Realizing this potential, depending on the nature of cell surface-dendrimer interactions, here we report controlled model membrane penetration and reorganization, using a model supported lipid bilayer and poly(ether imine) (PETIM) dendrimers of two generations. By systematically varying the areal density of the lipid bilayers, we provide a microscopic insight, through a combination of high resolution scattering, atomic force microscopy and atomistic molecular dynamics simulations, into the mechanism of PETIM dendrimer membrane penetration, pore formation and membrane re-organization induced by such interactions. Our work represents the first systematic observation of a regular barrel-like membrane spanning pore formation by dendrimers, tunable through lipid bilayer packing, without membrane disruption.

Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog

Background: The Bmi1 polycomb ring finger oncogene, a transcriptional repressor belonging to the Polycomb group of proteins plays an important role in the regulation of stem cell self-renewal and is elevated in several cancers. In the current study, we have explored the role of Bmi1 in regulating the stemness and drug resistance of breast cancer cells. Methods: Using real time PCR and immunohistochemistry primary breast tissues were analyzed. Retro-and lentiviruses were utilized to overexpress and knockdown Bmi1, RT-PCR and Western blot was performed to evaluate mRNA and protein expression. Stemness properties were analyzed by flow cytometry and sphere-formation and tumor formation was determined by mouse xenograft experiments. Dual luciferase assay was employed to assess promoter activity and MTT assay was used to analyze drug response. Results: We found Bmi1 overexpression in 64% of grade III invasive ductal breast adenocarcinomas compared to normal breast tissues. Bmi1 overexpression in immortalized and transformed breast epithelial cells increased their sphere-forming efficiency, induced epithelial to mesenchymal transition ( EMT) with an increase in the expression of stemness-related genes. Knockdown of Bmi1 in tumorigenic breast cells induced epithelial morphology, reduced expression of stemness-related genes, decreased the IC50 values of doxorubicin and abrogated tumor-formation. Bmi1-high tumors showed elevated Nanog expression whereas the tumors with lower Bmi1 showed reduced Nanog levels. Overexpression of Bmi1 increased Nanog levels whereas knockdown of Bmi1 reduced its expression. Dual luciferase promoter-reporter assay revealed Bmi1 positively regulated the Nanog and NF kappa B promoter activity. RT-PCR analysis showed that Bmi1 overexpression activated the NF kappa B pathway whereas Bmi1 knockdown reduced the expression of NF kappa B target genes, suggesting that Bmi1 might regulate Nanog expression through the NF kappa B pathway. Conclusions: Our study showed that Bmi1 is overexpressed in several high-grade, invasive ductal breast adenocarcinomas, thus supporting its role as a prognostic marker. While Bmi1 overexpression increased self-renewal and promoted EMT, its knockdown reversed EMT, reduced stemness, and rendered cells drug sensitive, thus highlighting a crucial role for Bmi1 in regulating the stemness and drug response of breast cancer cells. Bmi1 may control self-renewal through the regulation of Nanog expression via the NF kappa B pathway.

Exploring the potential of adjunct therapy in tuberculosis

A critical unmet need for treatment of drug-resistant tuberculosis (TB) is to find novel therapies that are efficacious, safe, and shorten the duration of treatment. Drug discovery approaches for TB primarily target essential genes of the pathogen Mycobacterium tuberculosis (Mtb) but novel strategies such as host-directed therapies and nonmicrobicidal targets are necessary to bring about a paradigm shift in treatment. Drugs targeting the host pathways and nonmicrobicidal proteins can be used only in conjunction with existing drugs as adjunct therapies. Significantly, host-directed adjunct therapies have the potential to decrease duration of treatment, as they are less prone to drug resistance, target the immune responses, and act via novel mechanism of action. Recent advances in targeting host-pathogen interactions have implicated pathways such as eicosanoid regulation and angiogenesis. Furthermore, several approved drugs such as metformin and verapamil have been identified that appear suitable for repurposing for the treatment of TB. These findings and the challenges in the area of host- and/or pathogen-directed adjunct therapies and their implications for TB therapy are discussed.

Resveratrol Metabolites Modify Adipokine Expression and Secretion in 3T3-L1 Pre-Adipocytes and Mature Adipocytes

Objective: Due to the low bioavailability of resveratrol, determining whether its metabolites exert any beneficial effect is an interesting issue. Methods: 3T3-L1 maturing pre-adipocytes were treated during differentiation with 25 mu M of resveratrol or with its metabolites and 3T3-L1 mature adipocytes were treated for 24 hours with 10 mM resveratrol or its metabolites. The gene expression of adiponectin, leptin, visfatin and apelin was assessed by Real Time RT-PCR and their concentration in the incubation medium was quantified by ELISA. Results: Resveratrol reduced mRNA levels of leptin and increased those of adiponectin. It induced the same changes in leptin secretion. Trans-resveratrol-3-O-glucuronide and trans-resveratrol-4'-O-glucuronide increased apelin and visfatin mRNA levels. Trans-resveratrol-3-O-sulfate reduced leptin mRNA levels and increased those of apelin and visfatin. Conclusions: The present study shows for the first time that resveratrol metabolites have a regulatory effect on adipokine expression and secretion. Since resveratrol has been reported to reduce body-fat accumulation and to improve insulin sensitivity, and considering that these effects are mediated in part by changes in the analyzed adipokines, it may be proposed that resveratrol metabolites play a part in these beneficial effects of resveratrol.

Statistical and econometric analysis of the treatment of HIV/AIDS

The epidemic of HIV/AIDS in the United States is constantly changing and evolving, starting from patient zero to now an estimated 650,000 to 900,000 Americans infected. The nature and course of HIV changed dramatically with the introduction of antiretrovirals. This discourse examines many different facets of HIV from the beginning where there wasn't any treatment for HIV until the present era of highly active antiretroviral therapy (HAART). By utilizing statistical analysis of clinical data, this paper examines where we were, where we are and projections as to where treatment of HIV/AIDS is headed.

Chapter Two describes the datasets that were used for the analyses. The primary database utilized was collected by myself from an outpatient HIV clinic. The data included dates from 1984 until the present. The second database was from the Multicenter AIDS Cohort Study (MACS) public dataset. The data from the MACS cover the time between 1984 and October 1992. Comparisons are made between both datasets.

Chapter Three discusses where we were. Before the first anti-HIV drugs (called antiretrovirals) were approved, there was no treatment to slow the progression of HIV. The first generation of antiretrovirals, reverse transcriptase inhibitors such as AZT (zidovudine), DDI (didanosine), DDC (zalcitabine), and D4T (stavudine) provided the first treatment for HIV. The first clinical trials showed that these antiretrovirals had a significant impact on increasing patient survival. The trials also showed that patients on these drugs had increased CD4+ T cell counts. Chapter Three examines the distributions of CD4 T cell counts. The results show that the estimated distributions of CD4 T cell counts are distinctly non-Gaussian. Thus distributional assumptions regarding CD4 T cell counts must be taken, into account when performing analyses with this marker. The results also show the estimated CD4 T cell distributions for each disease stage: asymptomatic, symptomatic and AIDS are non-Gaussian. Interestingly, the distribution of CD4 T cell counts for the asymptomatic period is significantly below that of the CD4 T cell distribution for the uninfected population suggesting that even in patients with no outward symptoms of HIV infection, there exists high levels of immunosuppression.

Chapter Four discusses where we are at present. HIV quickly grew resistant to reverse transcriptase inhibitors which were given sequentially as mono or dual therapy. As resistance grew, the positive effects of the reverse transcriptase inhibitors on CD4 T cell counts and survival dissipated. As the old era faded a new era characterized by a new class of drugs and new technology changed the way that we treat HIV-infected patients. Viral load assays were able to quantify the levels of HIV RNA in the blood. By quantifying the viral load, one now had a faster, more direct way to test antiretroviral regimen efficacy. Protease inhibitors, which attacked a different region of HIV than reverse transcriptase inhibitors, when used in combination with other antiretroviral agents were found to dramatically and significantly reduce the HIV RNA levels in the blood. Patients also experienced significant increases in CD4 T cell counts. For the first time in the epidemic, there was hope. It was hypothesized that with HAART, viral levels could be kept so low that the immune system as measured by CD4 T cell counts would be able to recover. If these viral levels could be kept low enough, it would be possible for the immune system to eradicate the virus. The hypothesis of immune reconstitution, that is bringing CD4 T cell counts up to levels seen in uninfected patients, is tested in Chapter Four. It was found that for these patients, there was not enough of a CD4 T cell increase to be consistent with the hypothesis of immune reconstitution.

In Chapter Five, the effectiveness of long-term HAART is analyzed. Survival analysis was conducted on 213 patients on long-term HAART. The primary endpoint was presence of an AIDS defining illness. A high level of clinical failure, or progression to an endpoint, was found.

Chapter Six yields insights into where we are going. New technology such as viral genotypic testing, that looks at the genetic structure of HIV and determines where mutations have occurred, has shown that HIV is capable of producing resistance mutations that confer multiple drug resistance. This section looks at resistance issues and speculates, ceterus parabis, where the state of HIV is going. This section first addresses viral genotype and the correlates of viral load and disease progression. A second analysis looks at patients who have failed their primary attempts at HAART and subsequent salvage therapy. It was found that salvage regimens, efforts to control viral replication through the administration of different combinations of antiretrovirals, were not effective in 90 percent of the population in controlling viral replication. Thus, primary attempts at therapy offer the best change of viral suppression and delay of disease progression. Documentation of transmission of drug-resistant virus suggests that the public health crisis of HIV is far from over. Drug resistant HIV can sustain the epidemic and hamper our efforts to treat HIV infection. The data presented suggest that the decrease in the morbidity and mortality due to HIV/AIDS is transient. Deaths due to HIV will increase and public health officials must prepare for this eventuality unless new treatments become available. These results also underscore the importance of the vaccine effort.

The final chapter looks at the economic issues related to HIV. The direct and indirect costs of treating HIV/AIDS are very high. For the first time in the epidemic, there exists treatment that can actually slow disease progression. The direct costs for HAART are estimated. It is estimated that the direct lifetime costs for treating each HIV infected patient with HAART is between $353,000 to $598,000 depending on how long HAART prolongs life. If one looks at the incremental cost per year of life saved it is only $101,000. This is comparable with the incremental costs per year of life saved from coronary artery bypass surgery.

Policy makers need to be aware that although HAART can delay disease progression, it is not a cure and HIV is not over. The results presented here suggest that the decreases in the morbidity and mortality due to HIV are transient. Policymakers need to be prepared for the eventual increase in AIDS incidence and mortality. Costs associated with HIV/AIDS are also projected to increase. The cost savings seen recently have been from the dramatic decreases in the incidence of AIDS defining opportunistic infections. As patients who have been on HAART the longest start to progress to AIDS, policymakers and insurance companies will find that the cost of treating HIV/AIDS will increase.

Pharmacogenetics of MicroRNAs and MicroRNAs Biogenesis Machinery in Pediatric Acute Lymphoblastic Leukemia

Despite the clinical success of acute lymphoblastic leukemia (ALL) therapy, toxicity is frequent. Therefore, it would be useful to identify predictors of adverse effects. In the last years, several studies have investigated the relationship between genetic variation and treatment-related toxicity. However, most of these studies are focused in coding regions. Nowadays, it is known that regions that do not codify proteins, such as microRNAs (miRNAs), may have an important regulatory function. MiRNAs can regulate the expression of genes affecting drug response. In fact, the expression of some of those miRNAs has been associated with drug response. Genetic variations affecting miRNAs can modify their function, which may lead to drug sensitivity. The aim of this study was to detect new toxicity markers in pediatric B-ALL, studying miRNA-related polymorphisms, which can affect miRNA levels and function. We analyzed 118 SNPs in pre-miRNAs and miRNA processing genes in association with toxicity in 152 pediatric B-ALL patients all treated with the same protocol (LAL/SHOP). Among the results found, we detected for the first time an association between rs639174 in DROSHA and vomits that remained statistically significant after FDR correction. DROSHA had been associated with alterations in miRNAs expression, which could affect genes involved in drug transport. This suggests that miRNA-related SNPs could be a useful tool for toxicity prediction in pediatric B-ALL.

Mapeamento de proteínas alvo para novos antifúngicos na fração microssomal e citosólica do patógeno humano Aspergillus fumigatus

A incidência de infecções fúngicas invasivas vem aumentando nos últimos anos. Estas infecções, em geral, apresentam altas taxas de mortalidade. A profilaxia com antifúngicos ainda é a estratégia mais comum na contenção da mortalidade e prevenção contra infecções fúngicas invasivas, porém, apresenta baixa eficiência, e relatos de resistência às drogas. Além disso, a terapia antifúngica é limitada a um pequeno grupo de drogas, como os polienos, azóis e equinocandinas. Desta forma, a busca de novos alvos de drogas é fundamental para o desenvolvimento de novos antifúngicos. Estudos in silico indicaram quatro genes como potenciais alvo de drogas em fungos patogênicos. Neste contexto, o objetivo deste trabalho foi verificar a expressão das proteínas codificadas por dois destes possíveis genes alvo, a proteína erg6, na fração microssomal, e trr1, na fração citosólica, em hifas de A. fumigatus. Visando alcançar este objetivo, foram primeiramente padronizadas todas as etapas de fracionamento celular visando isolar estas duas subfrações celulares de A. fumigatus. Posteriormente, foi otimizado o protocolo de extração e reidratação de proteínas microssomais bem como reidratação de proteínas citosólicas. Estes extratos foram submetidos a diferentes protocolos de fracionamento proteico em um sistema de eletroforese OFFGEL (OGE). Os resultados de Western immunoblot mostraram que estas duas proteínas, erg6 e trr1, são de fato expressas na fase filamentosa de A. fumigatus. O extrato proteico da fração microssomal submetido ao OGE em doze subfrações apresentou três subunidades da proteína erg6, reconhecidas pelo anticorpo monoclonal, com massas moleculares e pI distintos: uma subunidade de aproximadamente 79 kDa com pI entre 5,91 e 6,49, e outras duas subunidades de aproximadamente 35 kDa e 32 kDa, ambas com pI entre 6,49 e 7,08. A enzima erg6 foi descrita como um homotetrâmero em outros fungos. Porém, nossos resultados sugerem que, em A. fumigatus, a erg6 possui uma estrutura heterotetramérica. Quanto à proteína trr1, tanto no extrato total quanto nas frações resultantes do fracionamento em OGE, uma banda única de aproximadamente 40 kDa, com pI na faixa de 4,79 e 5,33, foi reconhecida pelo anticorpo policlonal. Desta forma, esta proteína parece ter uma estrutura homodimérica, assim como descrito em outros micro-organismos.

Fatores preditores de abandono de tratamento de tuberculose: uma metanálise

A tuberculose (TB) é uma doença que foi declarada pela Organização Mundial de Saúde como emergência mundial em 1993. As ferramentas disponíveis hoje para controle da TB são: o diagnóstico precoce e o tratamento eficiente. Porém, o abandono do tratamento de TB é um problema enfrentado mundialmente em proporções que podem variar entre 3% a 80%. Por isso, a identificação dos fatores que são preditores do abandono do tratamento de TB pode ajudar a desenvolver melhores estratégias para o seu controle. O objetivo deste trabalho é, através de uma metanálise, fazer uma estimativa sumária da medida de associação entre cada um dos fatores (a) relacionados ao serviço de saúde, (b) relacionado ao quadro clínico e à terapia da TB e (c) relacionados aos indivíduos e o abandono do tratamento de TB. A estratégia de busca eletrônica remota para a recuperação de publicações relevantes foi desenvolvida de forma específica para as diferentes bases consideradas relevantes (MEDLINE [Pubmed] e LILCS). Buscas por referências cruzadas, além da consulta à base de revisões sistemáticas COCHRANE, também foram realizadas. Investigações foram incluídas se fossem trabalhos observacionais ou experimentais que estudem fatores de risco ou preditores do desfecho de interesse (abandono do tratamento de tuberculose) através de comparações de dois ou mais grupos e se seus dados pudessem ser extraídos. Dois revisores classificaram os trabalhos e extraíram dados de forma mascarada e as discordâncias resolvidas. Mais de 190 textos completos foram aptos à combinação de dados. Destes, foi possível extrair dados para combinação de 40 exposições. Destas, 19 foram demonstradas nesta investigação. Das 19 demonstradas, 13 exposições estudadas apresentaram associação e poderiam ser considerados preditores (sexo masculino, alcoolismo, infecção pelo HIV/SIDA, uso de drogas ilícitas, nacionalidade estrangeira, analfabetismo, retratamento, baciloscopia positiva, abandono prévio, tratamento de curta duração, acesso fácil à unidade de saúde, treinamento para adesão, tuberculose extrapulmonar) e seis não apresentaram associação (desemprego, efeitos adversos, tuberculose resistente, necessidade de hospitalização, demora para o início do tratamento, espera longa para a consulta). Porém, essas associações devem ser consideradas de forma conservadora devido à elevada heterogeneidade encontrada em todas as exposições. Apenas cinco exposições apresentaram explicação parcial e uma apresentou explicação total para a heterogeneidade. O viés de publicação foi detectado em apenas duas das 19 exposições.

Saúde pública, inovação farmacêutica e propriedade intelectual: o desenvolvimento de um novo medicamento contra a malária no Brasil

Esta dissertação tem como objetivo estudar a relação entre propriedade intelectual, inovação e saúde pública, com foco na análise do consórcio farmacêutico para desenvolvimento do medicamento combinação em dose fixa artesunato-mefloquina (ASMQ) contra a malária. A concepção dessa iniciativa se insere num momento histórico, final dos anos 1990 e início dos anos 2000, em que estudos apontaram a insuficiência da pesquisa e desenvolvimento para as doenças negligenciadas. Na época, o cenário da malária era particularmente preocupante, dada a disseminação de resistência aos medicamentos disponíveis e à falta de perspectiva do lançamento de novos produtos contra a doença. Para proteger a última classe de antimaláricos eficazes, a saber,os derivados a base de artemisinina, uma estratégia encontrada foi a do recurso à terapia combinada a base de artemisinina (artemisinin based combination therapy ACT). Contudo, dos 4 ACTs recomendados pela OMS em 2001, apenas 1 se encontrava disponível no mercado. O projeto FACT foi então criado, em 2002, com o propósito de desenvolver dois novos ACTs artesunato-mefloquina e artesunato-amodiaquina. O consórcio do ASMQ, por suas especificidades, em particular a produção de inovação por um laboratório público do Sul e a circulação Sul-Sul de conhecimentos e tecnologias , o tornam de interesse para estudos nos campos da bioética e da saúde pública; tendo sido, por isso, escolhido como objeto desta dissertação. O estudo se apoiou em pesquisa bibliográfica, de fundamental relevância para a compreensão dos problemas de acesso e de disponibilidade de novos produtos para doenças negligenciadas, decorrentes de um modelo de inovação farmacêutica sustentado em patentes. De forma complementar, foram feitos: i) trabalho de observação durante a 65a Assembleia Mundial da Saúde, da Organização Mundial da Saúdem, evento de importância para os debates sobre propriedade intelectual e interesse público; e ii) entrevistas com integrantes de equipes das duas principais instituições participantes do consórcio FACT (Farmanguinhos/Fiocruz e DNDi).

Diversidade de respostas de Corynebacterium diphtheriae frente a agentes oxidantes: resistência, adaptação e envolvimento do determinante de resistência ao telurito (TeR) e do sistema OxyR na virulência bacteriana

Corynebacterium diphtheriae é um importante patógeno humano e agente causal da difteria. Embora seja observada uma redução mundial no número de casos da doença, a difteria permanece endêmica em muitos países e surtos são esporadicamente notificados. No Brasil, o último surto ocorreu no estado no Maranhão e revelou mudanças em aspectos clínico-epidemiológicos da doença. Diferentemente da maioria das cepas de difteria brasileiras, que pertencem ao biovar mitis, nesse surto dois diferentes pulsotipos de C. diphtheriae biovar intermedius foram isolados. Além disso, sinais patognomônicos da doença não foram relatados em parte dos casos. C. diphtheriae também vem sendo relacionado com quadros de infecções invasivas, apesar de ser reconhecido como patógeno tipicamente extracelular. Em conjunto, estas mudanças no perfil das infecções por C. diphtheriae sugerem a existência de outros fatores de virulência além da produção da toxina diftérica. Neste sentindo, foram realizadas análises de tipagem molecular e de genômica comparativa para avaliar a diversidade genética e o potencial de virulência de cepas de C. diphtheriae isoladas de difteria clássica e infecções invasivas. Os resultados obtidos demonstram a circulação de diferentes clones invasores no Brasil. Além disso, revelaram diferenças marcantes na presença e na composição de ilhas de patogenicidade entre as amostras, bem como nos genes sob regulação do DtxR e nas sequências dos corinefagos integradas ao cromossomo bacteriano. Uma vez que o potencial invasor bacteriano e a persistência no ambiente podem estar relacionados à tolerância ao estresse oxidativo, foram procurados nos genomas sequenciados, genes possivelmente envolvidos neste processo. Dentre estes, os genes DIP0906, predito como gene de resistência ao oxidante telurito (TeO32-), e DIP1421, codificador do regulador transcricional OxyR, foram caracterizados funcionalmente e tiveram seus papéis na patogenicidade investigados. Ensaios in vivo utilizando o nematódeo Caenorhabditis elegans demonstraram que ambos são importantes para a virulência de C. diphtheriae. Além da resistência ao TeO32, DIP0906 parece contribuir para a resistência ao peróxido de hidrogênio (H2O2) e para a viabilidade no interior de células respiratórias humanas. Já OxyR, além de controlar negativamente a resposta ao H2O2, parece estar envolvido com a ligação de C. diphtheriae a proteínas plasmáticas e de matriz extracelular. Adicionalmente, foi investigada resistência e a capacidade de adaptação de C. diphtheriae frente a agentes oxidantes, através da indução de resposta adaptativa e/ou resistência cruzada e da formação de biofilme. As cepas de C. diphtheriae apresentaram diferentes níveis de resistência e um comportamento heterogêneo na presença dos agentes oxidantes, o que sugere a existência de diferentes estratégias de sobrevivência e adaptação de C. diphtheriae nas condições de estresse oxidativo.

向日葵 (Helianthus annuus L.) 种质资源相关的基础研究

向日葵原产自北美,通过人工培育,形成了具有不同遗传多态性的品种,是一种集观赏、药用、食用、油用于一体，经济价值很高的资源植物。前人已经利用传统育种、辐射育种以及现代生物技术手段对向日葵种质资源的开发和保护进行了深入研究，这也加速了向日葵新品种的选育。随着离子注入等新型辐射方式的出现，离子注入对向日葵的诱变育种研究逐渐成为向日葵新品种选育的一个新增长点。另外，作为世界四大油料作物之一，向日葵种子老化问题一直存在于向日葵种质资源保存过程。向日葵种子作为向日葵的主要物质储存库，除了含有丰富的油、脂肪酸外，还含有丰富的维生素E资源。提高向日葵种子维生素E含量可以延长向日葵种子保存时间，也可以提高向日葵的经济价值。本文以向日葵种子为实验材料，分别用蛋白质组学的方法和生理方法对N+注入后向日葵种子、人工衰老向日葵种子以及向日葵种子成熟过程中维生素E代谢进行了初步分析。 对N+注入后向日葵种子蛋白质组变异研究发现，对照种子蛋白中的No.29特异蛋白与MADS盒转录因子HAM59有23.48%的匹配率;处理种子中的No.279特异蛋白与亮氨酸拉链蛋白的同源蛋白HAHB-4有23.20%的匹配率。说明离子注入能引起向日葵种胚蛋白质组水平上的变异，以期对离子注入的诱变机制进行初步探讨，为进一步探讨离子注入对于DNA及蛋白质的是否存在诱变热点提供一些初步的证据。 种子在高温和高含水量情况下曝露数天诱发的加速衰老比一般衰老引起更多的生化分解;另一方面，在长期贮存条件下的低温贮存环境和种子低含水量可能使种子处于玻璃态。种子胞质的极高粘度和低分子运动能够阻止或抑制很多有害过程。尽管种子衰老的生理机制已有大量研究，但衰老过程中的主要过程和相互作用仍未完全清楚。本文报道向日葵种子在较宽范围的含水量和温度条件下的脂过氧化、非酶蛋白糖基化对种子衰老的影响;同时，对种子玻璃态在长期贮存中对生化分解的阻滞作用并由此延长种子存活力也进行了探讨;与此同时我们借用蛋白质组学手段对加速老化的向日葵种子进行蛋白质组变异分析，结果发现随着老化程度的加深，出现部分蛋白含量随之增加，同时老化速率随之下降。通过质谱鉴定发现其中两个蛋白分别与resistance gene analog NBS4和 NBS5具有一定的同源性。因此我们推测，在加速老化过程中，亦可出现一些延缓老化的蛋白质，同时这些蛋白的出现是否标志着加速老化过程中也存在“玻璃态”有待于进一步的证实。 另外，我们以20份向日葵种质资源为实验材料，通过对维生素E含量、含油率、皮壳率以及百粒重的测定及统计分析，试图了解向日葵种质资源中维生素E含量变异及相关数据。结果表明，在20份向日葵种质资源中，油葵的维生素E含量和含油率明显高于食葵;含油率与维生素E含量在0.01水平呈极显著正相关，含油率与百粒重在0.05水平呈显著负相关;百粒重与皮壳率在0.01水平呈极显著负相关。通过初步评价，发现3份富含天然维生素E的向日葵种质。为了提高向日葵种子中维生素E含量，我们对向日葵胚胎发育过程中维生素E的积累以及短时高温对维生素E代谢的影响做了分析。我们发现，生育酚含量在开花后12到33天期间呈线性增长，并于33天后基本达到最大值，直至种子成熟。在上述生育酚增长期，我们将以每7天作为一个时间单位，对向日葵种胚发育过程进行高温处理。我们发现，高温对维生素E积累具有明显的刺激作用（以干重为基础）。但是由于在开花后12到19天之内高温处理会极大的影响干重的增加，因此当温度超过35℃时，生育酚总量还是大大下降的。然而，35℃的高温在向日葵开花后12到19天内并没有影响种胚的干重，而大大提高了单粒种子中的生育酚含量。因此，这些结果说明，我们可以调整播种时间提高向日葵中生育酚的含量，从而提高向日葵油的品质和向日葵种质的价值。

The trouble with antibiotics and pesticides is...

The paper discusses the output of the meeting on the use of chemicals in aquaculture in Asia. The effects of chemical use on cultured stocks in the farm, the immediate environment through discharges and effluents, surrounding areas, farm staff, consumers and drug resistance organisms are also discussed. It also shows how an antibiotic-resistant microorganism develops as the result of indiscriminate use of antibiotics.

Three-piece-ligation PCR and application in disruption of chlorophyll synthesis genes in Synechocystis sp PCC 6803

Linear DNA, consisting of a drug-resistance marker and long flanking sequences, was synthesized by one-step polymerase chain reaction after a three-piece ligating reaction. Chlorophyll synthesis genes, chlH and chIL in Synechocystis sp. PCC 6803, were replaced by a kanamycin-resistance marker through double recombinations with flanking homology regions. Under LAHG conditions, the chIL but not chlH mutant stopped chlorophyll synthesis, while both synthesized chlorophyll in the light.